Author | Hannah Slater


Novel regimen shows potential in mCRPC with androgen signaling inhibitor resistance

August 28, 2020

Treatment with the pan-BET bromodomain inhibitor ZEN-3694 plus enzalutamide may re-sensitize patients to androgen receptor–targeting agents.

Hydrogel spacer may reduce rectal irradiation in patients receiving RT for prostate cancer

July 30, 2020

Injection of an absorbable perirectal hydrogel spacer prior to radiotherapy for prostate cancer may reduce rectal irradiation and the associated rectal toxic effects that manifest clinically after longer-term follow-up.

Risk of skeletal-related events in mCRPC not associated with race

July 14, 2020

A study found no association between Black race and risk of skeletal-related events and all-cause mortality in men with newly diagnosed, bone metastatic castration-resistant prostate cancer.

Novel PSMA-targeted radioligand therapy shows promise in mCRPC

June 24, 2020

177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.